US20020092583A1 - Medical devices, particularly stents, and methods for their manufacture - Google Patents

Medical devices, particularly stents, and methods for their manufacture Download PDF

Info

Publication number
US20020092583A1
US20020092583A1 US09/760,595 US76059501A US2002092583A1 US 20020092583 A1 US20020092583 A1 US 20020092583A1 US 76059501 A US76059501 A US 76059501A US 2002092583 A1 US2002092583 A1 US 2002092583A1
Authority
US
United States
Prior art keywords
alloy
treatment
component
stent
surface region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/760,595
Inventor
Alan Pelton
Christine Trepanier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitinol Development Corp
Original Assignee
Nitinol Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitinol Development Corp filed Critical Nitinol Development Corp
Priority to US09/760,595 priority Critical patent/US20020092583A1/en
Assigned to NITINOL DEVELOPMENT CORPORATION reassignment NITINOL DEVELOPMENT CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PELTON, ALAN R., TREPANIER, CHRISTINE
Priority to CA002367790A priority patent/CA2367790A1/en
Priority to AU10200/02A priority patent/AU1020002A/en
Priority to EP02250311A priority patent/EP1222901A3/en
Publication of US20020092583A1 publication Critical patent/US20020092583A1/en
Priority to US10/683,377 priority patent/US20040117001A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23CCOATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C8/00Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
    • C23C8/06Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases
    • C23C8/08Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases only one element being applied
    • C23C8/10Oxidising
    • C23C8/16Oxidising using oxygen-containing compounds, e.g. water, carbon dioxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/006Resulting in heat recoverable alloys with a memory effect
    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23FNON-MECHANICAL REMOVAL OF METALLIC MATERIAL FROM SURFACE; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL; MULTI-STEP PROCESSES FOR SURFACE TREATMENT OF METALLIC MATERIAL INVOLVING AT LEAST ONE PROCESS PROVIDED FOR IN CLASS C23 AND AT LEAST ONE PROCESS COVERED BY SUBCLASS C21D OR C22F OR CLASS C25
    • C23F1/00Etching metallic material by chemical means
    • CCHEMISTRY; METALLURGY
    • C25ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25DPROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
    • C25D11/00Electrolytic coating by surface reaction, i.e. forming conversion layers
    • C25D11/02Anodisation
    • C25D11/26Anodisation of refractory metals or alloys based thereon
    • CCHEMISTRY; METALLURGY
    • C25ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25DPROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
    • C25D11/00Electrolytic coating by surface reaction, i.e. forming conversion layers
    • C25D11/02Anodisation
    • C25D11/34Anodisation of metals or alloys not provided for in groups C25D11/04 - C25D11/32
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077Special surfaces of prostheses, e.g. for improving ingrowth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol

Definitions

  • This invention relates to medical devices and to a method of making medical devices. More particularly, this invention relates to stents and a method for making stents. Most particularly, this invention relates to self-expanding Ni—Ti stents and methods for making such stents.
  • nickel containing alloys in medical devices is well established.
  • such alloys are nickel-titanium-based alloys, which are used because of their ability to exhibit shape memory properties associated with transformations between the martensitic and austenitic phases. These properties include thermally induced changes in configuration in which an article is first deformed from a heat-stable configuration to a heat-unstable configuration while the alloy is in its martensitic phase. Subsequent exposure to increased temperature results in a change in configuration from the heat-unstable configuration towards the original heat-stable configuration as the alloy reverts from its martensite phase to its austenite phase.
  • Shape memory alloys can also exhibit enhanced elastic properties compared with materials that do not exhibit martensite-austenite transformations.
  • the nature of the superelastic transformations of shape memory alloys is discussed in “Engineering Aspects of Shape Memory Alloys”, T. W. Duerig et al, 370, Butterworth-Heinemann (1990). Subject matter disclosed in that document is incorporated herein by reference.
  • a principal transformation of shape memory alloys involves an initial increase in strain, approximately linearly with stress. This behavior is reversible, and corresponds to conventional elastic deformation. Subsequent increases in strain are accompanied by little or no increase in stress, over a limited range of strain to the end of the “loading plateau”. The inflection point on a stress v.
  • strain graph defines the loading plateau stress. Subsequent increases in strain are accompanied by increases in stress. Upon unloading, there is a decline in stress with reducing strain to the start of the “unloading plateau” evidenced by the existence of an inflection point along which stress changes little with reducing strain. At the end of the unloading plateau, stress reduces, with reducing strain. The inflection point on the stress v. graph also defines the unloading plateau stress. Any residual strain after unloading to zero stress is the “permanent set” of the sample.
  • Characteristics of this deformation are established, and are defined in, for example, “Engineering Aspects of Shape Memory Alloys”, supra at 376.
  • Ni—Ti alloys are considered biocompatible. However, it can be desirable for some applications to use an alloy in which the nickel content is outside the range considered acceptable for in vivo use, in particular to achieve a desired physical behavior in the alloy.
  • One recently employed method to obtain a low-Ni, biocompatible surface is to use electrochemical methods.
  • One particular concept described by this invention is to disclose alternative means to simultaneously decrease Ni content and increase biocompatibility in Ni—Ti alloys.
  • the present invention provides medical devices whose biocompatibility in relation to nickel content is improved.
  • the invention provides a medical device which includes a component formed from an alloy which contains at least about 40% Ni, the alloy in a 10 nm deep surface region of the component containing not more than about 10% Ni.
  • the reduction of the nickel content of the alloy in a surface region of the Ni-alloy component can make the device of the invention more easily accepted for in vivo use by reducing the risk of toxic or carcinogenic side effects and by preventing its physical degradation.
  • the Ni content in the said surface region is reduced to not more than about 5%, more preferably not more than about 3%, especially not more than about 1.5%.
  • the alloy from which the component is formed is a Ni—Ti based alloy, for example a Ni—Ti binary alloy.
  • the alloy can contain more than two elements, for example a ternary alloy or a quaternary alloy.
  • elements that can be included in a Ni—Ti based alloy include Fe, Cu, Co, Zr, Hf, B and Nb.
  • the alloy contains at least about 48% Ni, more, preferably at least about 50%.
  • An example of a particularly preferred alloy is a binary alloy containing about 50.8% Ni.
  • Ni content in the surface region can be determined by known spectroscopic techniques such as Auger spectroscopy, X-ray Photoelectron Spectroscopy (XPS) or Secondary Ion Mass spectroscopy (SIMS). The content is measured in a 10 nm deep layer over the area in which the component has been treated.
  • XPS X-ray Photoelectron Spectroscopy
  • SIMS Secondary Ion Mass spectroscopy
  • the invention provides a method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component.
  • Ni content of the alloy in the said surface region can be reduced by specialized oxidizing treatments.
  • treatments to which the component can be exposed include exposure to a chemical solution, exposure to superheated steam, and an electrochemical treatment.
  • Such treatments can cause alloy elements other than nickel to be oxidized, to form an oxide layer on the component.
  • these treatments will effectively remove surface Ni atoms, thereby promoting the oxidation of Ti.
  • treatment of a Ni—Ti alloy can result in the formation of a surface layer of TiO 2 .
  • a treatment which involves exposure to superheated steam will preferably involve exposure for at least about 1.5 hours, preferably at least about 3 hours, more preferably at least about 5 hours.
  • the steam is heated to at least about 120 ⁇ C., more preferably at least about 150 ⁇ C.
  • the component is preferably included in an electrochemical system as the anode.
  • the component is preferably immersed in acidic or basic solutions to modify the surface chemistry.
  • the Ni alloy component of the device is preferably treated so that it exhibits shape memory properties making it suitable for the particular application for the device.
  • the component can be treated so that it exhibits a thermally induced change in configuration as a result of a change in phase between austenite and martensite phases due to a change in temperature.
  • the component will be treated so that it exhibits enhanced elastic properties such as those referred to as “superelastic” properties.
  • the medical device of the invention can be designed for any of a large number of applications.
  • a particularly preferred device is a stent formed from an alloy, which has been treated so that it exhibits enhanced elastic properties.
  • a stent can be inserted into a lumen while constrained in a transversely compressed configuration, and then allowed to expand so that it contacts the wall of the lumen to support it, and in some applications, also radially forced outwardly.
  • the stent is left in situ in the lumen to provide this support to the lumen.
  • FIG. 1 is a perspective view of a stent made according to the process described herein.
  • Ni—Ti alloys containing between 50% and 60% nickel by weight, are currently of great interest to the medical industry due to their superelastic and shape memory properties. These properties provide value for the design of various medical implants, such as stents, suture and bone anchors, archwire, and orthopaedic devices. As is well understood, implants made from these alloys require highly biocompatible surface finishes. Among the requirements of high biocompatibility are low uniform corrosion rates, high resistance to localized corrosion, low toxicity, and low thrombogenicity.
  • Unalloyed nickel is considered a toxic and carcinogenic substance. While NiTi alloys contain high nickel content, such a characteristic does not result in toxicity per se. In order to be toxic, nickel must be released to the environment of the device through corrosion processes. Thrombogenicity is a complicated matter, depending on the design of the device, the environment, surface chemistry and surface roughness.
  • Ni-free in this case, is defined as less than 5% nickel in the top 10 nm of the material.
  • the process consists of two steps: polishing and oxidizing.
  • the polishing process should be a polishing step that removes the existing oxide layer and leaves a surface finish of RMS 2 or better.
  • One preferred method would be to electropolish in acidic solutions at temperatures below room temperature. These colder temperature processes result in a lower material removal rate. Lower material removal rates are more conducive to polishing complex parts with small cross sectional areas. (Larger material removal rates dictate larger currents. These cannot be uniformly carried through small cross sectional areas without excessive heating.) Polishing may be improved by preceding treatments to remove oxide layers, such as mechanical polishing and/or chemical etching.
  • the oxidation process can consist of a steam sterilization treatment, or better a surface treatment in a chemical solution, or even better an anodizing process. All these processes remove the Nickel from the surface and leave behind a surface film of Rutile (TiO 2 ). Immersion of the Ni—Ti component in an acidic or basic chemical solution will selectively remove the existing surface layer and promote the formation of TiO 2 . Anodizing appears to significantly reduce the corrosion current in the passive regime and increase the corrosion potential toward more noble values.
  • a stent is made from a tube of a Ni—Ti binary alloy.
  • a stent 10 which may be formed according to the described invention is seen in FIG. 1.
  • the tube from which the stent is formed is made from a Ni—Ti binary alloy which contains 50.8% Ni by weight.
  • the tube has an external diameter of about 3 mm and a wall thickness of about 0.4 mm. Any conventional tube forming techniques, such as drawing, etching, etc, may be used to form the tube.
  • a pattern is cut into the tube so that it adopts a configuration similar to that described in FIG. 1, in which there are slots 12 cut out of the tube.
  • Conventional etching and laser cutting techniques may be used to create slots 12 into the tube, so that it forms stent 10 .
  • These slots 12 enable the radial dimension of the tube to be changed by causing the struts 14 to deform relative to one another.
  • stents such as the Palmaz® stent, Palmaz-Schatz® stent, Crown® stent, and Bx Velocity® stent, all made by the parent company of the present assignee, and incorporated herein by reference, are all suitable designs of stents for the herein described process.
  • Suitable cutting techniques include laser machining (for example using a YAG laser), electric discharge machining, chemical etching and machining.
  • the stent is treated so that the alloy exhibits superelastic properties by a process that includes a succession of cold working and heat treatment steps (such as those found in Duerig et al., U.S. Pat. No. 5,843,244. owned by a common assignee and incorporated herein by reference.)
  • the stent is cold worked by fitting it onto a succession of mandrels of increasing sizes.
  • the stent is heat treated after each cold working step by exposing it to an elevated temperature (that is below the re-crystallization temperature of the alloy) while it is constrained in the configuration resulting from the cold work.
  • a suitable heat treatment temperature is in the range 400° C. to 450° C.
  • a succession of cold work and heat treatment steps can be used to impart an appropriate amount of cold work to the stent, which could result in a permanent deformation if carried out in a single step.
  • the stent After the cold work and heat treatment steps, the stent has superelastic properties so that it can be deformed inwardly towards the configuration as cut, and will then recover elastically towards the configuration from which it was deformed inwardly.
  • the stent 10 could then be electropolished at temperatures below 20° C. using methanol-sulfuric acid solutions. If necessary, the stent 10 may be “primed” for polishing, by using prior treatments to remove oxide layers, such as mechanical methods (e.g., grit blasting) and/or chemical etching.
  • the Ni content in the alloy in a surface region of the stent is reduced is by an oxidizing treatment involving exposure to superheated steam at 150° C. for 12 hours.
  • the stent surface resulting from this treatment contains TiO 2 . From Auger spectroscopy, the Ni content in a surface region 10 nm deep has been found to be less than 2% by weight.
  • the sulfuric acid bath can be adequately substituted with other acid-based solutions, such as HNO 3 , perchloric acid, etc.
  • the concept applied by this step is to place the medical device into the solution bath, apply a potential, and use the device as an anode in the process.
  • electropolishing selectively removes base material, which may contain contaminants, and allows re-growth of the passive oxide on the device surface with a low Nickel content contained thereon.
  • electromechanical methods described above may further be substituted with purely chemical methods. For instance, one may use one of the following solutions:
  • Acidic e.g., 10% to 50% HNO 3 (preferably 20% to 40% HNO 3 ; more preferably 30% HNO 3 —water solution);
  • Neutral e.g., saline-based, such as 0.2% to 5% NaCl, preferably 0.5% to 1.5% NaCl, more preferably 0.9% NaCl—water solution;
  • the step may include anodizing.
  • This includes exposure of the medical device to a chemical solution (acidic, neutral or basic) with an appropriately applied potential in order to grow a more stable passive oxide layer.
  • a chemical solution acidic, neutral or basic
  • an appropriately applied potential in order to grow a more stable passive oxide layer.
  • one procedure would be to immerse the NiTi medical device in a saline-based solution, and hold the potential at about 200 mV to 1000 mV, preferably 300 mV to 700 mV, more preferably 500 mV for 0.1 to 10 hours, preferably 0.2 to 2 hours, more preferably 0.5 to 1 hour.

Abstract

A medical device which includes a component formed from an alloy which contains at least about 40% Ni by weight. The alloy in a 10 nm deep surface region of the component contains not more than about 10% Ni by weight. The Ni content in that surface region can be reduced by polishing and oxidizing treatment such as (a) exposure to superheated steam, or (b) immersion in a chemical solution, or (c) an electrochemical treatment, using the device as the anode in a solution bath with a current running therethrough.

Description

    FIELDS OF THE INVENTION
  • This invention relates to medical devices and to a method of making medical devices. More particularly, this invention relates to stents and a method for making stents. Most particularly, this invention relates to self-expanding Ni—Ti stents and methods for making such stents. [0001]
  • BACKGROUND OF THE INVENTION
  • The use of nickel containing alloys in medical devices is well established. Examples of such alloys are nickel-titanium-based alloys, which are used because of their ability to exhibit shape memory properties associated with transformations between the martensitic and austenitic phases. These properties include thermally induced changes in configuration in which an article is first deformed from a heat-stable configuration to a heat-unstable configuration while the alloy is in its martensitic phase. Subsequent exposure to increased temperature results in a change in configuration from the heat-unstable configuration towards the original heat-stable configuration as the alloy reverts from its martensite phase to its austenite phase. [0002]
  • Shape memory alloys can also exhibit enhanced elastic properties compared with materials that do not exhibit martensite-austenite transformations. The nature of the superelastic transformations of shape memory alloys is discussed in “Engineering Aspects of Shape Memory Alloys”, T. W. Duerig et al, 370, Butterworth-Heinemann (1990). Subject matter disclosed in that document is incorporated herein by reference. A principal transformation of shape memory alloys involves an initial increase in strain, approximately linearly with stress. This behavior is reversible, and corresponds to conventional elastic deformation. Subsequent increases in strain are accompanied by little or no increase in stress, over a limited range of strain to the end of the “loading plateau”. The inflection point on a stress v. strain graph defines the loading plateau stress. Subsequent increases in strain are accompanied by increases in stress. Upon unloading, there is a decline in stress with reducing strain to the start of the “unloading plateau” evidenced by the existence of an inflection point along which stress changes little with reducing strain. At the end of the unloading plateau, stress reduces, with reducing strain. The inflection point on the stress v. graph also defines the unloading plateau stress. Any residual strain after unloading to zero stress is the “permanent set” of the sample. Characteristics of this deformation, the loading plateau, the unloading plateau, the elastic modulus, the plateau length and the permanent set (defined with respect to a specific total deformation) are established, and are defined in, for example, “Engineering Aspects of Shape Memory Alloys”, supra at 376. [0003]
  • Many Ni—Ti alloys are considered biocompatible. However, it can be desirable for some applications to use an alloy in which the nickel content is outside the range considered acceptable for in vivo use, in particular to achieve a desired physical behavior in the alloy. One recently employed method to obtain a low-Ni, biocompatible surface is to use electrochemical methods. One particular concept described by this invention is to disclose alternative means to simultaneously decrease Ni content and increase biocompatibility in Ni—Ti alloys. [0004]
  • SUMMARY OF THE INVENTION
  • The present invention provides medical devices whose biocompatibility in relation to nickel content is improved. [0005]
  • Accordingly, in one aspect, the invention provides a medical device which includes a component formed from an alloy which contains at least about 40% Ni, the alloy in a 10 nm deep surface region of the component containing not more than about 10% Ni. [0006]
  • It has been found that the reduction of the nickel content of the alloy in a surface region of the Ni-alloy component can make the device of the invention more easily accepted for in vivo use by reducing the risk of toxic or carcinogenic side effects and by preventing its physical degradation. Preferably, the Ni content in the said surface region is reduced to not more than about 5%, more preferably not more than about 3%, especially not more than about 1.5%. [0007]
  • Preferably, the alloy from which the component is formed is a Ni—Ti based alloy, for example a Ni—Ti binary alloy. However, the alloy can contain more than two elements, for example a ternary alloy or a quaternary alloy. Examples of elements that can be included in a Ni—Ti based alloy include Fe, Cu, Co, Zr, Hf, B and Nb. [0008]
  • Preferably, the alloy contains at least about 48% Ni, more, preferably at least about 50%. An example of a particularly preferred alloy is a binary alloy containing about 50.8% Ni. [0009]
  • The Ni content in the surface region can be determined by known spectroscopic techniques such as Auger spectroscopy, X-ray Photoelectron Spectroscopy (XPS) or Secondary Ion Mass spectroscopy (SIMS). The content is measured in a 10 nm deep layer over the area in which the component has been treated. [0010]
  • In another aspect, the invention provides a method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component. [0011]
  • The Ni content of the alloy in the said surface region can be reduced by specialized oxidizing treatments. Whereas, several investigators have tried to improve corrosion resistance by thermal oxidation heat treatments, there has been little success. Examples of treatments to which the component can be exposed include exposure to a chemical solution, exposure to superheated steam, and an electrochemical treatment. Such treatments can cause alloy elements other than nickel to be oxidized, to form an oxide layer on the component. Simultaneously, these treatments will effectively remove surface Ni atoms, thereby promoting the oxidation of Ti. For example, treatment of a Ni—Ti alloy can result in the formation of a surface layer of TiO[0012] 2.
  • A treatment which involves exposure to superheated steam will preferably involve exposure for at least about 1.5 hours, preferably at least about 3 hours, more preferably at least about 5 hours. Preferably, the steam is heated to at least about 120□ C., more preferably at least about 150□ C. [0013]
  • In electrochemical treatments of the alloy, the component is preferably included in an electrochemical system as the anode. [0014]
  • In chemical treatments of the alloy, the component is preferably immersed in acidic or basic solutions to modify the surface chemistry. [0015]
  • The Ni alloy component of the device is preferably treated so that it exhibits shape memory properties making it suitable for the particular application for the device. For example, the component can be treated so that it exhibits a thermally induced change in configuration as a result of a change in phase between austenite and martensite phases due to a change in temperature. For many applications, the component will be treated so that it exhibits enhanced elastic properties such as those referred to as “superelastic” properties. [0016]
  • The medical device of the invention can be designed for any of a large number of applications. A particularly preferred device is a stent formed from an alloy, which has been treated so that it exhibits enhanced elastic properties. A stent can be inserted into a lumen while constrained in a transversely compressed configuration, and then allowed to expand so that it contacts the wall of the lumen to support it, and in some applications, also radially forced outwardly. The stent is left in situ in the lumen to provide this support to the lumen. The reduction of the risk of complications due to adverse biocompatibility reactions that can be achieved by the present invention gives rise to particular advantages in a device that is used in this way.[0017]
  • DESCRIPTION OF THE DRAWINGS
  • The invention will be better understood by reference to the drawings, in which: [0018]
  • FIG. 1 is a perspective view of a stent made according to the process described herein.[0019]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Ni—Ti alloys, containing between 50% and 60% nickel by weight, are currently of great interest to the medical industry due to their superelastic and shape memory properties. These properties provide value for the design of various medical implants, such as stents, suture and bone anchors, archwire, and orthopaedic devices. As is well understood, implants made from these alloys require highly biocompatible surface finishes. Among the requirements of high biocompatibility are low uniform corrosion rates, high resistance to localized corrosion, low toxicity, and low thrombogenicity. [0020]
  • Unalloyed nickel is considered a toxic and carcinogenic substance. While NiTi alloys contain high nickel content, such a characteristic does not result in toxicity per se. In order to be toxic, nickel must be released to the environment of the device through corrosion processes. Thrombogenicity is a complicated matter, depending on the design of the device, the environment, surface chemistry and surface roughness. [0021]
  • The process according to the current invention describes a process to produce a very smooth and Ni-free surface on Ni—Ti. “Ni-free” in this case, is defined as less than 5% nickel in the top 10 nm of the material. The process consists of two steps: polishing and oxidizing. [0022]
  • Ideally, the polishing process should be a polishing step that removes the existing oxide layer and leaves a surface finish of RMS 2 or better. One preferred method would be to electropolish in acidic solutions at temperatures below room temperature. These colder temperature processes result in a lower material removal rate. Lower material removal rates are more conducive to polishing complex parts with small cross sectional areas. (Larger material removal rates dictate larger currents. These cannot be uniformly carried through small cross sectional areas without excessive heating.) Polishing may be improved by preceding treatments to remove oxide layers, such as mechanical polishing and/or chemical etching. [0023]
  • The oxidation process can consist of a steam sterilization treatment, or better a surface treatment in a chemical solution, or even better an anodizing process. All these processes remove the Nickel from the surface and leave behind a surface film of Rutile (TiO[0024] 2). Immersion of the Ni—Ti component in an acidic or basic chemical solution will selectively remove the existing surface layer and promote the formation of TiO2. Anodizing appears to significantly reduce the corrosion current in the passive regime and increase the corrosion potential toward more noble values.
  • The present invention can perhaps best be understood by reference to an example of a stent made according to the disclosed processes. [0025]
  • EXAMPLE 1
  • The invention is described by way of a stent is made from a tube of a Ni—Ti binary alloy. (A stent [0026] 10 which may be formed according to the described invention is seen in FIG. 1.)
  • The tube from which the stent is formed is made from a Ni—Ti binary alloy which contains 50.8% Ni by weight. The tube has an external diameter of about 3 mm and a wall thickness of about 0.4 mm. Any conventional tube forming techniques, such as drawing, etching, etc, may be used to form the tube. [0027]
  • A pattern is cut into the tube so that it adopts a configuration similar to that described in FIG. 1, in which there are [0028] slots 12 cut out of the tube. Conventional etching and laser cutting techniques may be used to create slots 12 into the tube, so that it forms stent 10. These slots 12 enable the radial dimension of the tube to be changed by causing the struts 14 to deform relative to one another. (It is also well understood that a segment of wire may be formed into slots 12, so that the effect of the expansion is identical to the slots formed by other processes.) Other suitable configurations of stents will be apparent; for example, stents such as the Palmaz® stent, Palmaz-Schatz® stent, Crown® stent, and Bx Velocity® stent, all made by the parent company of the present assignee, and incorporated herein by reference, are all suitable designs of stents for the herein described process. Suitable cutting techniques include laser machining (for example using a YAG laser), electric discharge machining, chemical etching and machining.
  • The stent is treated so that the alloy exhibits superelastic properties by a process that includes a succession of cold working and heat treatment steps (such as those found in Duerig et al., U.S. Pat. No. 5,843,244. owned by a common assignee and incorporated herein by reference.) The stent is cold worked by fitting it onto a succession of mandrels of increasing sizes. The stent is heat treated after each cold working step by exposing it to an elevated temperature (that is below the re-crystallization temperature of the alloy) while it is constrained in the configuration resulting from the cold work. A suitable heat treatment temperature is in the range 400° C. to 450° C. A succession of cold work and heat treatment steps can be used to impart an appropriate amount of cold work to the stent, which could result in a permanent deformation if carried out in a single step. [0029]
  • After the cold work and heat treatment steps, the stent has superelastic properties so that it can be deformed inwardly towards the configuration as cut, and will then recover elastically towards the configuration from which it was deformed inwardly. [0030]
  • The stent [0031] 10 could then be electropolished at temperatures below 20° C. using methanol-sulfuric acid solutions. If necessary, the stent 10 may be “primed” for polishing, by using prior treatments to remove oxide layers, such as mechanical methods (e.g., grit blasting) and/or chemical etching.
  • The Ni content in the alloy in a surface region of the stent is reduced is by an oxidizing treatment involving exposure to superheated steam at 150° C. for 12 hours. The stent surface resulting from this treatment contains TiO[0032] 2. From Auger spectroscopy, the Ni content in a surface region 10 nm deep has been found to be less than 2% by weight.
  • Further electromechanical methods of polishing medical devices according to this invention are certainly possible and even likely. For instance, the sulfuric acid bath can be adequately substituted with other acid-based solutions, such as HNO[0033] 3, perchloric acid, etc. Basically, the concept applied by this step is to place the medical device into the solution bath, apply a potential, and use the device as an anode in the process. Under proper conditions, electropolishing selectively removes base material, which may contain contaminants, and allows re-growth of the passive oxide on the device surface with a low Nickel content contained thereon.
  • The electromechanical methods described above may further be substituted with purely chemical methods. For instance, one may use one of the following solutions: [0034]
  • Acidic, e.g., 10% to 50% HNO[0035] 3 (preferably 20% to 40% HNO3; more preferably 30% HNO3—water solution);
  • Neutral, e.g., saline-based, such as 0.2% to 5% NaCl, preferably 0.5% to 1.5% NaCl, more preferably 0.9% NaCl—water solution; [0036]
  • Basic, e.g., NaOH solutions. [0037]
  • The purpose of these solutions is to provide a chemical environment to “leach” excess Nickel and other contaminants from the existing oxide surface and allow growth of a more passive (TiO[0038] 2) oxide layer. Again, these surfaces possess lower Nickel content than the levels present in typical NiTi medical devices.
  • In addition, the step may include anodizing. This includes exposure of the medical device to a chemical solution (acidic, neutral or basic) with an appropriately applied potential in order to grow a more stable passive oxide layer. For example, one procedure would be to immerse the NiTi medical device in a saline-based solution, and hold the potential at about 200 mV to 1000 mV, preferably 300 mV to 700 mV, more preferably 500 mV for 0.1 to 10 hours, preferably 0.2 to 2 hours, more preferably 0.5 to 1 hour. [0039]
  • Of course, it is to be understood that a broad range of equivalent steps are quite possible by which to make stents according to the present invention. For instance, the rates of polishing may be adjusted depending on the desired surface finish. Also, the length of time to heat the stent with superheated steam may be adjusted depending on the size of the stent, or the number of stents heated in a batch. Furthermore, for chemical treatments, the volume of solution and duration of exposure will be adjusted according to the number of stents and the prior processing steps. What is to be realized is that the present invention is to be determined from the appended claims and their equivalents. [0040]

Claims (19)

What is claimed is:
1. A medical device which includes a component formed from an alloy which contains at least about 40% Ni by weight, the device having a 10 nm deep surface region of containing not more than about 5% Ni by weight.
2. A device as claimed in claim 1, in which the alloy in the said surface region contains not more than about 3% Ni.
3. A device as claimed in claim 1, in which the alloy has been subjected to polishing and oxidizing treatment on said surface region.
4. A device as claimed in claim 3, in which the said polishing treatment comprises an electrochemical or mechanical treatment.
5. A device as claimed in claim 3, in which the said oxidizing treatment comprises at the steps of exposure to superheated steam, a chemical treatment and an electrochemical treatment.
6. A device as claimed in claim 1, in which the alloy is a Ni—Ti based alloy.
7. The device of claim 5, in which the said electrochemical oxidizing treatment comprises anodizing in a acidic, neutral or basic solution.
8. A device as claimed in claim 1, in which the device has been treated so that it exhibits superelastic properties.
9. A device as claimed in claim 1, in which the alloy contains at least about 48% Ni by weight.
10. A device as claimed in claim 9, in which the alloy contains at least about 50% Ni by weight.
11. A device as claimed in claim 1, in the form of a stent.
12. A method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component.
13. The method of claim 12 wherein said device is a stent.
14. A method as claimed in claim 12, in which the component is exposed to superheated steam.
15. A method as claimed in claim 14, in which the component is exposed to steam for at least about 3 hours.
16. A method as claimed in claim 14, in which the steam is heated to at least about 120° C.
17. A method as claimed in claim 13, in which the said treatment comprises a chemical treatment, in which the device is immersed in an acidic, neutral or basic chemical solution bath.
18. A method as claimed in claim 17, in which the said treatment comprises a chemical treatment, in which the device is immersed for at least about 0.5 hour.
19. A method as claimed in claim 12, in which the said treatment comprises an electrochemical treatment, in which the device is included in an electrochemical system as an anode in a solution bath with current running therethrough.
US09/760,595 2001-01-16 2001-01-16 Medical devices, particularly stents, and methods for their manufacture Abandoned US20020092583A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/760,595 US20020092583A1 (en) 2001-01-16 2001-01-16 Medical devices, particularly stents, and methods for their manufacture
CA002367790A CA2367790A1 (en) 2001-01-16 2002-01-15 Medical devices, particularly stents and methods for their manufacture
AU10200/02A AU1020002A (en) 2001-01-16 2002-01-16 Medical devices, particularly stents, and methods for their manufacture
EP02250311A EP1222901A3 (en) 2001-01-16 2002-01-16 Medical devices and methods for their manufacture
US10/683,377 US20040117001A1 (en) 2001-01-16 2003-10-10 Medical devices, particularly stents, and methods for their manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/760,595 US20020092583A1 (en) 2001-01-16 2001-01-16 Medical devices, particularly stents, and methods for their manufacture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/683,377 Continuation-In-Part US20040117001A1 (en) 2001-01-16 2003-10-10 Medical devices, particularly stents, and methods for their manufacture

Publications (1)

Publication Number Publication Date
US20020092583A1 true US20020092583A1 (en) 2002-07-18

Family

ID=25059578

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/760,595 Abandoned US20020092583A1 (en) 2001-01-16 2001-01-16 Medical devices, particularly stents, and methods for their manufacture

Country Status (4)

Country Link
US (1) US20020092583A1 (en)
EP (1) EP1222901A3 (en)
AU (1) AU1020002A (en)
CA (1) CA2367790A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050098444A1 (en) * 2003-11-12 2005-05-12 Schaeffer Darin G. Electropolishing apparatus and method for medical implants
US20080082158A1 (en) * 2006-09-28 2008-04-03 Cook Incorporated Method for Deployment of a Stent Graft
US10106908B1 (en) * 2017-04-10 2018-10-23 Ryszard Rokicki Nitinol fatigue resistance using electropolishing, magnetoelectropolishing, anodizing and magnetoanodizing or combinations thereof under oxygen evolution regime

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402173B2 (en) 2000-09-18 2008-07-22 Boston Scientific Scimed, Inc. Metal stent with surface layer of noble metal oxide and method of fabrication
US7101391B2 (en) 2000-09-18 2006-09-05 Inflow Dynamics Inc. Primarily niobium stent
US20040117001A1 (en) * 2001-01-16 2004-06-17 Pelton Alan R. Medical devices, particularly stents, and methods for their manufacture
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
US7488343B2 (en) 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
US8137397B2 (en) 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
ES2251312B1 (en) * 2004-10-04 2007-07-01 Universitat Politecnica De Catalunya NEW TREATMENT OF OXIDATION IN ALLOYS OF NITI FOR THE DECREASE OF THE RELEASE OF IONS NI AND THE IMPROVEMENT OF BIOCOMPATIBILITY.
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
EP2959925B1 (en) 2006-09-15 2018-08-29 Boston Scientific Limited Medical devices and methods of making the same
CA2663303A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
ES2368125T3 (en) 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS.
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
EP2277563B1 (en) 2006-12-28 2014-06-25 Boston Scientific Limited Bioerodible endoprostheses and method of making the same
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
WO2014088944A1 (en) * 2012-12-03 2014-06-12 The Regents Of The University Of California Devices, systems and methods for coating surfaces
CN113042975B (en) * 2021-03-08 2023-07-28 沛县盛玛特新材料研究院有限公司 Treatment method for improving surface quality of medical metal stent and medical metal stent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3617360A (en) * 1968-11-29 1971-11-02 Gen Electric High temperature metallic diffusion coating and method
US4148699A (en) * 1976-07-20 1979-04-10 Heritage Silversmiths Limited Electropolishing of stainless steel
US4612061A (en) * 1984-03-15 1986-09-16 Kabushiki Kaisha Toshiba Method of manufacturing picture tube shadow mask
US4774150A (en) * 1986-03-07 1988-09-27 Kabushiki Kaisha Toshiba Thermal barrier coating
US4799127A (en) * 1986-07-29 1989-01-17 Tdk Corporation Semiconductive ceramic composition and semiconductor ceramic capacitor
US5277788A (en) * 1990-10-01 1994-01-11 Aluminum Company Of America Twice-anodized aluminum article having an organo-phosphorus monolayer and process for making the article
US5630887A (en) * 1995-02-13 1997-05-20 Novacor Chemicals Ltd. Treatment of furnace tubes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1076763C (en) * 1998-09-09 2001-12-26 北京航空航天大学 In-situ preparing of insulating film on surface of marmem

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3617360A (en) * 1968-11-29 1971-11-02 Gen Electric High temperature metallic diffusion coating and method
US4148699A (en) * 1976-07-20 1979-04-10 Heritage Silversmiths Limited Electropolishing of stainless steel
US4612061A (en) * 1984-03-15 1986-09-16 Kabushiki Kaisha Toshiba Method of manufacturing picture tube shadow mask
US4774150A (en) * 1986-03-07 1988-09-27 Kabushiki Kaisha Toshiba Thermal barrier coating
US4799127A (en) * 1986-07-29 1989-01-17 Tdk Corporation Semiconductive ceramic composition and semiconductor ceramic capacitor
US4854936A (en) * 1986-07-29 1989-08-08 Tdk Corporation Semiconductive ceramic composition and semiconductive ceramic capacitor
US5277788A (en) * 1990-10-01 1994-01-11 Aluminum Company Of America Twice-anodized aluminum article having an organo-phosphorus monolayer and process for making the article
US5630887A (en) * 1995-02-13 1997-05-20 Novacor Chemicals Ltd. Treatment of furnace tubes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050098444A1 (en) * 2003-11-12 2005-05-12 Schaeffer Darin G. Electropolishing apparatus and method for medical implants
US7252746B2 (en) 2003-11-12 2007-08-07 Cook Incorporated Electropolishing apparatus and method for medical implants
US20070209929A1 (en) * 2003-11-12 2007-09-13 Cook Incorporated Electropolishing apparatus and method for medical implants
US20100181206A1 (en) * 2003-11-12 2010-07-22 Cook Incorporated Method of electropolishing medical implants
US7799201B2 (en) 2003-11-12 2010-09-21 Cook Incorporated Method of electropolishing medical implants
US7799183B2 (en) 2003-11-12 2010-09-21 Cook Incorporated Electropolishing apparatus and method for medical implants
US20080082158A1 (en) * 2006-09-28 2008-04-03 Cook Incorporated Method for Deployment of a Stent Graft
US20080082159A1 (en) * 2006-09-28 2008-04-03 Cook Incorporated Stent for Endovascular Procedures
US20080082154A1 (en) * 2006-09-28 2008-04-03 Cook Incorporated Stent Graft Delivery System for Accurate Deployment
US10106908B1 (en) * 2017-04-10 2018-10-23 Ryszard Rokicki Nitinol fatigue resistance using electropolishing, magnetoelectropolishing, anodizing and magnetoanodizing or combinations thereof under oxygen evolution regime

Also Published As

Publication number Publication date
EP1222901A3 (en) 2002-07-24
AU1020002A (en) 2002-07-18
CA2367790A1 (en) 2002-07-16
EP1222901A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
US20020092583A1 (en) Medical devices, particularly stents, and methods for their manufacture
US20040117001A1 (en) Medical devices, particularly stents, and methods for their manufacture
US11015253B2 (en) Surface treatment process for implants made of titanium alloy
US6679980B1 (en) Apparatus for electropolishing a stent
Zhao et al. Electrochemical polishing of 316L stainless steel slotted tube coronary stents
CA2499453C (en) Balloon expandable superelastic stent
Raval et al. Development and assessment of 316LVM cardiovascular stents
EP1355685B1 (en) Radiopaque nitinol alloys for medical devices
US20090010796A1 (en) Long fatigue life nitinol
JP2007516772A (en) Metal alloy cleaning and polishing method and product cleaned or polished thereby
WO2005104993A2 (en) Amorphous oxide surface film for metallic implantable devices and method for production thereof
EP2885074B1 (en) Surface oxide removal methods
Biscarini et al. Enhanced nitinol properties for biomedical applications
JP2007006941A (en) Medical material and its manufacturing method
Mani et al. Surface finishing of N itinol for implantable medical devices: A review
US20130092555A1 (en) Removal of an island from a laser cut article
US20130004362A1 (en) Process for production of medical instrument, and medical instrument
JP5355972B2 (en) Stent manufacturing method
Sojitra et al. Surface enhancement and characterization of L-605 cobalt alloy cardiovascular stent by novel electrochemical treatment
Korolyov et al. Electrolytic plasma polishing of NiTi alloy
WO2011118401A1 (en) Process for production of medical instrument, and medical instrument
CN113042975B (en) Treatment method for improving surface quality of medical metal stent and medical metal stent
Kathuria Biocompatible metallic stent for medical therapy
Sholihin et al. Effect of annealing on surface oxidation of Ti-50.8 at% Ni shape memory alloy
Rondelli et al. Corrosion Behaviour of Nitinol Vascular Stents

Legal Events

Date Code Title Description
AS Assignment

Owner name: NITINOL DEVELOPMENT CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELTON, ALAN R.;TREPANIER, CHRISTINE;REEL/FRAME:011826/0486

Effective date: 20010511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION